Table 2.

Frequently reported AEs: AEs in ≥20% of patientsa

Motolimod starting dose, N (% of all patients)2.5 mg/m2 (n = 4)3.0 mg/m2 (n = 6)3.5 mg/m2 (n = 3)All (n = 13)
Flu-like symptoms3 (23)6 (46)3 (23)12 (92)
Injection site reaction3 (23)6 (46)3 (23)12 (92)
Fatigue3 (23)b6 (46)2 (15)11 (85)
Anorexia1 (8)3 (23)0 (0)4 (31)
Malaise0 (0)2 (15)2 (15)4 (31)
Arthralgia1 (8)1 (8)1 (8)3 (23)
Nausea2 (15)b2 (15)1 (8)5 (38)
Cough1 (8)3 (23)1 (8)5 (38)
Dehydration1 (8)2 (15)1 (8)4 (31)
Vomiting1 (8)b0 (0)2 (15)3 (23)
Oral pain1 (8)1 (8)1 (8)3 (23)
Rash3 (23)2 (15)0 (0)5 (38)
Dyspnea1 (8)1 (8)b1 (8)3 (23)
Dysphagia0 (0)3 (23)0 (0)3 (23)
Hypomagnesemia2 (15)1 (8)0 (0)3 (23)
  • aAll AEs were grade 1 or 2 except where noted.

  • bIncludes one incidence of grade 3 AE.